ZYNE - Zynerba Pharmaceuticals GAAP EPS of -$0.18 in-line

2023-03-28 07:52:01 ET

• Zynerba Pharmaceuticals press release ( NASDAQ: ZYNE ): Q4 GAAP EPS of -$0.18 in-line.
• As of December 31, 2022, cash and cash equivalents were $50.6 million, compared to $67.8 million as of December 31, 2021.
• Management believes that the Company’s cash and cash equivalents are sufficient to fund operations and capital requirements into mid-year 2024. Top-line results from the Company’s confirmatory pivotal Phase 3 RECONNECT trial of Zygel in patients with FXS are expected in the first half of 2024.
• Shares +5% PM.

For further details see: